Communiqués Navidea Biopharmaceuticals, Inc.

Actions

NAVB

US63937X2027

Marché Fermé - OTC Markets Autres places de cotation 21:17:33 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,0001 ^USD	-50,00 %		+19 900,00 %	-99,82 %

21/06	Navidea Biopharmaceuticals, Inc. annonce la démission de membres de son conseil d'administration	CI
2023	Navidea Biopharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois se terminant le 30 septembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	04/12	AQ
Navidea: Q3 Earnings Snapshot	15/11	AQ
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	06/10/23	BU
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	10/08/23	BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	31/07/23	AQ
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities	31/07/23	BU
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	29/07/23	BU
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	27/07/23	BU
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down	13/07/23	BU
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	03/07/23	AQ
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets	30/06/23	BU
NAVIDEA BIOPHARMACEUTICALS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	16/06/23	AQ
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock	16/06/23	BU
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment	16/06/23	BU
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update	07/06/23	BU
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	05/06/23	AQ
NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	05/06/23	AQ
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice	02/06/23	BU
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down	01/06/23	BU
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market	23/05/23	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Navidea Biopharmaceuticals, Inc.

Actions

NAVB

US63937X2027

Communiqués

Filtres